News | August 12, 2011

U.K.'s First Total Artificial Heart Patient Discharged Using Freedom Portable Driver

August 12, 2011 — SynCardia Systems Inc., manufacturer of the temporary Total Artificial Heart (TAH), said Aug. 2, Papworth Hospital in Cambridge discharged the United Kingdom's first TAH patient. He was sent home to wait for a matching donor heart with his wife and 5-year-old son using the Freedom portable driver.

"Two years ago I was cycling nine miles to work and nine miles back every day, but by the time I was admitted to hospital, I was struggling to walk even a few yards," said patient Matthew Green. "I am really excited about going home and just being able to do the everyday things that I haven't been able to do for such a long time, such as playing in the garden with my son and cooking a meal for my family."

Green, 40, suffered from arrhythmogenic right ventricular cardiomyopathy (ARVC), a heart muscle disease resulting in arrhythmia, heart failure and sudden death. His health had been declining over recent years, with a heart transplant being his only option.

"Matthew's condition was deteriorating rapidly and we discussed with him the possibility of receiving this device, because without it he may not have survived the wait until a suitable donor heart could be found for him," said Steven Tsui, consultant cardiothoracic surgeon and director of the transplant service. "The operation went extremely well and Matthew has made an excellent recovery."

On June 9, Green became the first patient in the United Kingdom to receive the Total Artificial Heart. Two months later, he was discharged from the hospital using the Freedom portable driver. Weighing 13.5 pounds, including two onboard lithium-ion batteries, it is the world's first wearable portable driver designed to power the TAH both inside and outside the hospital. The driver is CE approved for use in Europe and undergoing a U.S. Food and Drug Administration (FDA)-approved investigational device exemption (IDE) clinical study in the United States.

Papworth Hospital is the first and only hospital in the UK certified to implant the TAH. The hospital performed the UK's first heart transplant in 1979 and has been using mechanical devices to support patients with end-stage heart failure since the 1980s.

For more information: www.syncardia.com

Related Content

Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Overlay Init